ImmusanT to develop Type 1 diabetes vaccine with JDRF backing

Vaccine
JDRF plans to do more than just support ImmusanT with a VC investment, and will engage in a collaboration on the project. (Guschenkova / iStock / Getty Images)

ImmusanT is expanding its vaccine immunotherapy platform to include Type 1 diabetes, following an investment from the JDRF.

While the amount was undisclosed, it was the foundation’s first direct investment in both the company and in peptide-based immunotherapies, through its venture philanthropy-focused T1D Fund.

“We believe ImmusanT’s platform could deliver a transformative therapy for T1D, along with a better understanding of the antigens that are driving this disease,” said Jonathan Behr, managing director at the JDRF T1D Fund.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

“We will support the company beyond our capital investment, collaborating to ensure ImmusanT has the highest chance of success,” Behr added.

RELATED: ImmusanT goes on hiring spree ahead of phase 2 celiac vaccine trial

With the money, ImmusanT hopes to translate insights from its celiac disease program into the development of a novel vaccine for Type 1 diabetes.

The company’s lead vaccine, Nexvax2, has shown safety and activity in phase 1 studies in celiac disease, a disorder that shares many similarities with Type 1 diabetes—both are linked to types of genetically inherited human leukocyte antigens, which encode certain regulators of the immune system and are associated with autoimmune diseases.

RELATED: Harnessing immunotherapy to reverse Type 1 diabetes

ImmusanT completed its first phase 1b trial of Nexvax2 in February 2017, aiming to protect celiac patients from the effects of exposure to gluten and symptoms such as diarrhea, abdominal pain and bloating. In 9 of out of 10 cases celiac disease is thought to be caused by a mutation in the HLA-DQ2 gene.

Suggested Articles

With the closure of its sixth venture capital round, the Swiss health data firm Sophia Genetics has added another $110 million to its coffers.

French biotech Genfit is on its way out of fatty liver R&D after a phase 3 flop, but compatriot Poxel is on its way up with a phase 2 win.

Genentech committed $200 million in upfront and near-term payments, plus up to $515 million in more distant milestones, for the exclusive rights.